February 4 is World Cancer Day. This year’s theme marks the second year of the campaign “Close the Care Gap” which is about understanding the inequities in cancer care and taking actions to make the necessary progress to address them.
With the passion of empowering people to lead healthier lives, Hi-Q has been investing in R&D of adjunct supplement for cancer patients to relieve the side effects from cachexia, to improve outcomes as patients progress through their cancer journey to cure or palliation.
Also, Hi-Q works continuously to improve society’s attitude to the prevention and treatment of cancer, providing ongoing and practical support to cancer patients and their families. We hope to contribute to a better future for the community, through our resources and actions.
__________________________
Making Difference in Cancer with Clinically Tested Adjunct Supplement!
Hi-Q has joined collaboration with PhD scientists and medical doctors in leading research institutions, universities hospitals for continue Oligo Fucoidan scientific studies and human clinical trials. The scientific studies result show that Oligo fucoidan, whether through in vitro to in vivo research studies or clinical trials in humans, has been proven to produce positive bioactive and synergy effects of adjuvant therapy on cancer treatment. This allows molecular mechanisms in cancer research to be applied in adjuvant cancer treatment, in line with the pursuit of translational medicine and the mindset of establishing a direct link between basic medical research and clinical application. Oligo Fucoidan also has attained its inclusion in the Dictionary of Drugs of the U.S. National Cancer Institute (NCI) (Code C170752).